Abstract
Basal cell carcinomas and squamous cell carcinomas are non-melanoma skin cancers reported to be among the most common malignancies, being responsible for high human morbidity. Conventional chemotherapy applied to these conditions shows non-specific targeting, thus severe adverse side effects are also commonly reported. New therapeutic strategies based on nanoparticulates technology have emerged as alternatives for site specific chemotherapy. Among the different types of nanoparticulates, lipid nanoemulsions and nanoparticles have several advantages for topical delivery of poorly soluble chemotherapeutics. These particles show sustained drug release and protection of loaded drugs from chemical degradation. This technology is promising to enhance the intracellular concentration of drugs and consequently reduce the cytotoxicity of skin chemotherapy.
Original language | English |
---|---|
Pages (from-to) | 417-424 |
Number of pages | 8 |
Journal | Clinical and Translational Oncology |
Volume | 15 |
Issue number | 6 |
DOIs | |
Publication status | Published - Jun 2013 |
Externally published | Yes |
Keywords
- Basal cell carcinomas (BCC)
- Lipid nanoemulsions (NEs) and nanoparticles (NPs)
- Nanocarriers
- Non-melanoma skin cancer
- Squamous cell carcinomas (SCC)